97% of all drug development projects fail before or during clinical trials. Especially for biologics, failures related to suboptimal candidates like insufficient potency, immunogenicity, toxic side effects or poor drug-like properties are the dominant cause of failure. Latentfusion.ai provides AI-guided lead optimization to biotech companies seeking to increase their chances to overcome these hurdles and bring therapeutics to the market. We employ smart, highly efficient protein design algorithms to help to unlock innovative therapies, alleviate patient burden and reduce drug prices.
The founding team currently consists of Elias Hagmann, who combines 15+ years of biotech experience with an algorithmic background from ETH Zürich. Market size is assumed to exceed USD 12 Billion.